Table 5.
Application of the proposed CPP design to the biosimilar trial of Humira
Scenario | Clinical Response |
Power |
Sample Size |
|||
---|---|---|---|---|---|---|
Humira | Test agent | CPP | NB | CPP | NB | |
1 | 0.608 | 0.608 | 81% | 67% | 190 | 188 |
2 | 0.486 | 0.486 | 76.4% | 74.4% | 256 | 259 |
3 | 0.608 | 0.486 | 4.3% | 4.6% | 140 | 137 |